Malkan, U. Y. Et Al. 2016. Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib. ANNALS OF PHARMACOTHERAPY , vol.50, no.4 , 336.

Malkan, U. Y. , GÜNEŞ, G., ETGÜL, S., Aslan, T., Aydin, S., & HAZNEDAROĞLU, İ. C. , (2016). Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib. ANNALS OF PHARMACOTHERAPY , vol.50, no.4, 336.

Malkan, MERT Et Al. "Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib," ANNALS OF PHARMACOTHERAPY , vol.50, no.4, 336, 2016

Malkan, MERT Et Al. "Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib." ANNALS OF PHARMACOTHERAPY , vol.50, no.4, pp.336, 2016

Malkan, U. Y. Et Al. (2016) . "Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib." ANNALS OF PHARMACOTHERAPY , vol.50, no.4, p.336.

@article{article, author={MERT EŞME Et Al. }, title={Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib}, journal={ANNALS OF PHARMACOTHERAPY}, year=2016, pages={336} }